Phase I Study of Fulvestrant in Combination with 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors (ESMO Asia 2026) - Oct 1, 2026 - Abstract #363P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Combination therapy • Metastases • P1 data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor
|
|
Chih-Yi A. Liao; Nicholas Feinberg; Janet Chin; Blase Polite; Sarah Martin; Aurelie Desgardin; Theodore Karrison; Jeffrey Minehart; Xavier Keutgen
|